The Food and Drug Administration approved the first-ever therapy for Glycogen Storage Disease Type Ia for patients aged 8 years and older on Aug. 19, ending decades without an approved pharmacological treatment for the rare metabolic condition.
GSD1a is a disorder in which the liver cannot properly release glucose, causing dangerous blood sugar drops, seizures and long-term organ damage if left untreated, the FDA said.
The approval represents a landmark for the estimated thousands of U.S. patients and their families who have managed the condition without any FDA-approved drug therapy. Prior treatment has relied entirely on dietary management, including frequent cornstarch feedings to maintain blood glucose levels.
The disease affects an estimated one in 100,000 individuals and is typically diagnosed in infancy or early childhood. Without careful dietary management, patients face life-threatening hypoglycemia, liver enlargement and kidney complications.
The FDA approved the therapy under its standard review pathway for rare diseases. The Orphan Drug Act provides incentives including market exclusivity and tax credits to encourage development of treatments for conditions affecting small patient populations.
For patients who have spent their lives adhering to grueling dietary regimens — often requiring feedings every few hours around the clock — an approved therapy could dramatically improve quality of life and reduce the constant risk of medical emergencies.
The approval also demonstrates continued FDA momentum on rare disease drug development, an area where patient advocacy groups have pressed for greater urgency over decades. The agency has approved a record pace of rare disease treatments in recent years.
The drug’s manufacturer and brand name should be confirmed from the FDA’s full approval announcement. Pricing and insurance coverage details were not included in the agency’s release.